To identify pharmacologic tumor PDL1-depleting drugs (PDDs), we screened the Prestwick and LOPAC molecule libraries, which are enriched for FDA-approved drugs, in order to identify those that depleted tumor PDL1 in distinct mouse and human cancer cell lines. Here, CD274 is linked to neoplasm.